Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
BACKGROUND
Dose modifications following adverse events (AEs) are an important part of the management of patients with pancreatic cancer treated with chemotherapy. While dose modifications are utilized to ensure patient safety, the subsequent influence of dose adjustments on treatment exposure and efficacy have not been reported in detail. This exploratory analysis examined the influence of dose modifications on treatment exposure and efficacy in the phase III MPACT trial, which demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) to Gem alone for the treatment of metastatic pancreatic cancer.


METHODS
Patients received either nab-P 125 mg/m(2) + Gem 1,000 mg/m(2) on days 1, 8, and 15 every 4 weeks or Gem 1,000 mg/m(2) weekly for the first 7 of 8 weeks (cycle 1) and then days 1, 8, and 15 every 4 weeks (cycle ≥2). The protocol allowed up to 2 dose reductions per agent. Dose delays were also used to manage toxicities.


RESULTS
Toxicities that most commonly led to dose modifications were neutropenia, peripheral neuropathy, thrombocytopenia, and fatigue for nab-P and neutropenia, thrombocytopenia, and fatigue for Gem alone. Baseline characteristics were similar in patients with dose modifications and the intent-to-treat (ITT) population. Among the 421 treated patients in the nab-P + Gem arm, all patients initiated treatment at the per-protocol nab-P starting dose of 125 mg/m(2); 172 (41%) had a nab-P dose reduction, and 300 (71%) had a nab-P dose delay during the study. Most dose modifications occurred after the first 3 months (2 cycles) of treatment. The majority of patients (104/172, 60%) required only 1 nab-P dose reduction, and over half of patients (163/300) had either 1 or 2 dose delays. Patients who underwent dose modifications of nab-P had greater treatment exposure than those who did not in terms of treatment duration, number of cycles administered, and cumulative dose of nab-P delivered. Overall survival (OS) was shorter in the nab-P + Gem arm for patients who did not vs. did undergo dose reduction [median, 6.9 vs. 11.4 months; hazard ratio (HR), 1.93; 95% CI, 1.53-2.44; P<0.0001] and for those who did not vs. did undergo a dose delay (median, 6.2 vs. 10.1, HR, 2.05; 95% CI, 1.60-2.63; P<0.0001). Progression-free survival (PFS) and overall response rate (ORR) were also improved in patients with dose modifications. Similar trends were observed in the Gem-alone arm. Multivariate analyses confirmed that both dose delay and dose reduction were significantly associated with OS.


CONCLUSIONS
This analysis suggests that although most doses of nab-P were given at the starting dose of 125 mg/m(2) the first 3 of 4 weeks, dose reductions and delays were effective when necessary to ameliorate toxicity allowing greater treatment exposure without compromising efficacy.
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Werner
W
Scheithauer
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Ramesh K
RK
Ramanathan
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Malcolm
M
Moore
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Teresa
T
Macarulla
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
David
D
Goldstein
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Pascal
P
Hammel
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Volker
V
Kunzmann
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Helen
H
Liu
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Desmond
D
McGovern
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Alfredo
A
Romano
1 Medizinische Universität Wien, Wien, Austria ; 2 Division of Hematology/Oncology, Mayo Clinic, Scottsdale, Arizona, USA ; 3 BC Cancer Agency, Vancouver, British Columbia, Canada ; 4 Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain ; 5 Prince of Wales Hospital, Sydney, NSW, Australia ; 6 Hôpital Beaujon, Clichy, France ; 7 Universitätsklinikum Würzburg, Würzburg, Germany ; 8 Celgene Corporation, Summit, New Jersey, USA ; 9 Celgene Corporation, Boudry, Switzerland ; 10 Translational Genomics Research Institute and Honor Health, Scottsdale, Arizona, USA.
Daniel D
DD
Von Hoff
Pancreatic cancer; dose delay; dose reduction; gemcitabine (Gem); nab-paclitaxel (nab-P)